Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA.
Identifieur interne : 000307 ( PubMed/Curation ); précédent : 000306; suivant : 000308Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA.
Auteurs : Sawsan S. Al-Amri [Arabie saoudite] ; Anwar M. Hashem [Arabie saoudite]Source :
- Methods in molecular biology (Clifton, N.J.) [ 1940-6029 ] ; 2020.
Abstract
Indirect enzyme-linked immunosorbent assay (ELISA) enables detection and quantification of antigen-specific antibodies in biological samples such as human or animal sera. Most current MERS-CoV serological assays such as neutralization, immunofluorescence, or protein microarray rely on handling of live MERS-CoV in high containment laboratories, highly trained personnel as well as the need for expensive and special equipment and reagents representing a hurdle for most laboratories especially when resources are limited. In this chapter, we describe a validated and optimized indirect ELISA protocol based on recombinant S1 subunit (amino acids 1-725) of MERS-CoV for qualitative and quantitative determination of MERS-CoV-binding antibodies.
DOI: 10.1007/978-1-0716-0211-9_11
PubMed: 31883093
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000307
Links to Exploration step
pubmed:31883093Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA.</title>
<author><name sortKey="Al Amri, Sawsan S" sort="Al Amri, Sawsan S" uniqKey="Al Amri S" first="Sawsan S" last="Al-Amri">Sawsan S. Al-Amri</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hashem, Anwar M" sort="Hashem, Anwar M" uniqKey="Hashem A" first="Anwar M" last="Hashem">Anwar M. Hashem</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:31883093</idno>
<idno type="pmid">31883093</idno>
<idno type="doi">10.1007/978-1-0716-0211-9_11</idno>
<idno type="wicri:Area/PubMed/Corpus">000307</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000307</idno>
<idno type="wicri:Area/PubMed/Curation">000307</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000307</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA.</title>
<author><name sortKey="Al Amri, Sawsan S" sort="Al Amri, Sawsan S" uniqKey="Al Amri S" first="Sawsan S" last="Al-Amri">Sawsan S. Al-Amri</name>
<affiliation wicri:level="1"><nlm:affiliation>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Hashem, Anwar M" sort="Hashem, Anwar M" uniqKey="Hashem A" first="Anwar M" last="Hashem">Anwar M. Hashem</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</nlm:affiliation>
<country xml:lang="fr">Arabie saoudite</country>
<wicri:regionArea>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Methods in molecular biology (Clifton, N.J.)</title>
<idno type="eISSN">1940-6029</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Indirect enzyme-linked immunosorbent assay (ELISA) enables detection and quantification of antigen-specific antibodies in biological samples such as human or animal sera. Most current MERS-CoV serological assays such as neutralization, immunofluorescence, or protein microarray rely on handling of live MERS-CoV in high containment laboratories, highly trained personnel as well as the need for expensive and special equipment and reagents representing a hurdle for most laboratories especially when resources are limited. In this chapter, we describe a validated and optimized indirect ELISA protocol based on recombinant S1 subunit (amino acids 1-725) of MERS-CoV for qualitative and quantitative determination of MERS-CoV-binding antibodies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">31883093</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>18</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1940-6029</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>2099</Volume>
<PubDate><Year>2020</Year>
</PubDate>
</JournalIssue>
<Title>Methods in molecular biology (Clifton, N.J.)</Title>
<ISOAbbreviation>Methods Mol. Biol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA.</ArticleTitle>
<Pagination><MedlinePgn>127-133</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/978-1-0716-0211-9_11</ELocationID>
<Abstract><AbstractText>Indirect enzyme-linked immunosorbent assay (ELISA) enables detection and quantification of antigen-specific antibodies in biological samples such as human or animal sera. Most current MERS-CoV serological assays such as neutralization, immunofluorescence, or protein microarray rely on handling of live MERS-CoV in high containment laboratories, highly trained personnel as well as the need for expensive and special equipment and reagents representing a hurdle for most laboratories especially when resources are limited. In this chapter, we describe a validated and optimized indirect ELISA protocol based on recombinant S1 subunit (amino acids 1-725) of MERS-CoV for qualitative and quantitative determination of MERS-CoV-binding antibodies.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Amri</LastName>
<ForeName>Sawsan S</ForeName>
<Initials>SS</Initials>
<AffiliationInfo><Affiliation>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hashem</LastName>
<ForeName>Anwar M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. amhashem@kau.edu.sa.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Methods Mol Biol</MedlineTA>
<NlmUniqueID>9214969</NlmUniqueID>
<ISSNLinking>1064-3745</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antibodies</Keyword>
<Keyword MajorTopicYN="Y">Antigens</Keyword>
<Keyword MajorTopicYN="Y">ELISA</Keyword>
<Keyword MajorTopicYN="Y">MERS-CoV</Keyword>
<Keyword MajorTopicYN="Y">Recombinant S1 subunit</Keyword>
<Keyword MajorTopicYN="Y">Serology</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31883093</ArticleId>
<ArticleId IdType="doi">10.1007/978-1-0716-0211-9_11</ArticleId>
<ArticleId IdType="pmc">PMC7122216</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Peptides. 2015 Oct;72:4-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25908411</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet Infect Dis. 2015 May;15(5):559-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25863564</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol Methods. 2019 Mar;466:41-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30659836</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Microbiol. 2017 Mar;55(3):172-182</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28243939</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Med Virol. 2018 Feb;90(2):367-371</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28906003</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Euro Surveill. 2015;20(41):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26538277</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Clin Infect Dis. 2014 Nov 1;59(9):1225-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24829216</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Sci Rep. 2017 Mar 23;7:44875</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28332568</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000307 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000307 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:31883093 |texte= Qualitative and Quantitative Determination of MERS-CoV S1-Specific Antibodies Using ELISA. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:31883093" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
This area was generated with Dilib version V0.6.33. |